Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319.

Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319.

Fibroblast growth factor 21 is a novel hormonal regulator with the potential to treat a broad variety of metabolic abnormalities, such as type 2 diabetes, obesity, hepatic steatosis, and cardiovascular disease. Human recombinant wild type FGF21 (FGF21) has been shown to ameliorate metabolic disorder...

Full description

Bibliographic Details
Main Authors: Alexei Kharitonenkov, John M Beals, Radmila Micanovic, Beth A Strifler, Radhakrishnan Rathnachalam, Victor J Wroblewski, Shun Li, Anja Koester, Amy M Ford, Tamer Coskun, James D Dunbar, Christine C Cheng, Christopher C Frye, Thomas F Bumol, David E Moller
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3594191?pdf=render

Internet

http://europepmc.org/articles/PMC3594191?pdf=render

Similar Items